HEALTH● LOW3d ago · Oct 28, 2026, 3:24 PM
mRNA Combo Cuts High-Risk Melanoma Relapse
Human Progress · global
“Adding a personalized mRNA-based cancer vaccine to immunotherapy after surgery for high-risk melanoma reduced the risk of recurrence or death by 42%, according to results from the phase III INTerpath-001 trial presented at the European Society for Medical Oncology (ESMO) Congress 2026 (Abstract LBA1). The vaccine, intismeran autogene, was given alongside pembrolizumab and compared with […] The post mRNA Combo Cuts High-Risk Melanoma Relapse appeared first on Human Progress.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH17m ago43 women rescued in illegal human egg harvesting racket in HyderabadThe HinduHEALTH1h agoAllergic reactions after sex should be listed as an antibiotic risk, experts sayNew ScientistHEALTH1h agoPreliminary reports suspect power leakage into pool from wiring for lights inside poolThe HinduHEALTH1h agoMore than 5,000 die from Ebola in DR Congo's deadliest outbreakBBC World